Palmoplantar pustulosishttps://en.wikipedia.org/wiki/Pustulosis_palmaris_et_plantaris
Palmoplantar pustulosis jẹ onibaje pustular dermatosis tí ń wáyé loorekoore (eyni ni, pustulosis tàbí psoriasis pustular) tí ó kan àwọn ọpẹ àti ẹsẹ̀ nikan, tí a ṣe afihan nípasẹ̀ àwọn pustules intraepidermal tí ó kún fún neutrophils. Lílò retinoids nìkan, àti ní àpapọ̀ pẹ̀lú photochemotherapy, lè mu ilọsiwaju àwọn ààmì aisan palmoplantar pustulosis.

○ Itọju
Acitretin tí a mu ní ẹnu jẹ́ dókò fún irú psoriasis yìí.
#Acitretin
☆ AI Dermatology — Free Service
Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
  • Ní ìdí èyí, pompholyx tún lè fura sí.
  • Ní àìní pustules, àléfọ́ ọwọ́ lè tún jẹ́ àyẹ̀wò gẹ́gẹ́ bí àyẹ̀wò ìyàtọ̀.
References Palmoplantar Psoriasis 28846363 
NIH
Palmoplantar psoriasis jẹ́ irú psoriasis tí ó kan awọ ara lórí ọwọ́ àti ẹsẹ̀ rẹ. Ó ń hàn gẹ́gẹ́ bí àwọ̀ tó ń dínà, tí ó lè jẹ́ gbigbẹ, rọ̀rọ̀, tàbí àpapọ̀ àwọn méjèèjì.
Palmoplantar psoriasis is a variant of psoriasis that characteristically affects the skin of the palms and soles. It features hyperkeratotic, pustular, or mixed morphologies.
 Tumor Necrosis Factor Inhibitors 29494032 
NIH
Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).